Journal
CURRENT OBSTETRICS AND GYNECOLOGY REPORTS
Volume 1, Issue 3, Pages 95-105Publisher
SPRINGER
DOI: 10.1007/s13669-012-0017-4
Keywords
Human papillomavirus; HPV; Vaccines; Cervical intraepithelial neoplasia; Duration of efficacy; Immunogenicity; Colposcopy; Loop electrical excisional procedure; LEEP
Categories
Funding
- Merck Co.
- GlaxoSmithKline, Inc.
Ask authors/readers for more resources
Cervical cancer kills women of all ages. The irrefutable link to oncogenic human papillomavirus (HPV), a sexually transmitted infection, forever changed society's attitude toward cervical cancer. The advent of HPV vaccines has brought the link of sexual practices and personal behavior to the forefront. The vaccines were aggressively marketed to parents, young girls, public health officials, physicians, and all payor sources before the scientific data defining their actual benefit could be delineated. At this early time, the HPV vaccines prevent persistent type-specific HPV infections, some abnormal Pap tests, some colposcopies, and some excisional procedures in women who are HPV-DNA negative before vaccination. Health-modeling exercises have demonstrated that duration of vaccine efficacy is the most important parameter for any long-term cancer prevention benefit. Implementation efforts have demonstrated that a three-dose series is difficult to achieve and results in a high vaccine wastage rate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available